In conversation with Paul Brennan
November 10, 2009 by leonardzehr · 3 Comments
On Oct. 22, long-time biotech executive Paul Brennan took over the reins of Migenix (TSX:MGI), clearly with his work cut out for him. In April, United Therapeutics walked away from an option agreement to develop Migenix’s Celgosivir anti-viral treatment for Hepatitis C. Then in May, Cadence Pharmaceuticals walked away from a deal to develop Migenix’s [...]
Listen to BioTuesdays 
